Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.52 |
| ▸ | CCR9 | P51686 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.48 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591285 | 0.89 | SLC40A1 (0.59) | CYP2D6CYP2C9LMNAKDM1ASLC40A1 | |
| SCHEMBL6824081 | 0.88 | CYP2D6 (0.60) | CYP2D6CYP2C9LMNAKDM1ASLC40A1 | |
| SCHEMBL14601698 | 0.88 | LMNA (0.56) | CYP2D6CYP2C9LMNAKIF11KMT2A | |
| SCHEMBL8513283 | 0.83 | CYP2C9 (0.55) | CYP2D6CYP2C9LMNASLC40A1PTGES2 | |
| SCHEMBL9209669 | 0.81 | LMNA (0.58) | LMNAKEAP1NFE2L2MEN1MAPT | |
| SCHEMBL5801171 | 0.81 | LMNA (0.61) | LMNAKEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL1818184 | 0.78 | METAP2 (0.62) | LMNAMEN1MAPTKMT2ATHRB | |
| SCHEMBL16592647 | 0.78 | ATIC (0.56) | LMNAKEAP1NFE2L2MEN1MAPT | |
| SCHEMBL7577535 | 0.78 | CA1 (0.65) | CYP2C9LMNAMEN1MAPTKMT2A | |
| SCHEMBL22256871 | 0.77 | SLC40A1 (0.50) | CYP2D6CYP2C9LMNAKDM1ASLC40A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON INC. | 2012-06-28 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129404-B2 | Compounds and uses thereof | PLEXXIKON INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2406260-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | PLEXXIKON, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104973-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | PLEXXIKON, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234418-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2D6 2421/4885CYP2C9 1862/4885LMNA 3161/4885 |
| US-20120165366-A1 | COMPOUNDS AND USES THEREOF | BRAF, PKD1, RAF1 | CYP2D6 2421/4885CYP2C9 1862/4885LMNA 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.